Sweden
· Delayed Price · Currency is SEK · Price in DKK DanCann Pharma Statistics
Total Valuation
DanCann Pharma has a market cap or net worth of SEK 8.31 million. The enterprise value is 3.14 million.
| Market Cap | 8.31M |
| Enterprise Value | 3.14M |
Important Dates
The last earnings date was Friday, April 4, 2025.
| Earnings Date | Apr 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DanCann Pharma has 3.99 million shares outstanding. The number of shares has increased by 2,718.02% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 3.99M |
| Shares Change (YoY) | +2,718.02% |
| Shares Change (QoQ) | +158.97% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 3.28% |
| Float | 3.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.73 |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.25 |
| EV / Sales | 0.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.54
| Current Ratio | 2.54 |
| Quick Ratio | 2.16 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.36 |
Financial Efficiency
Return on equity (ROE) is -69.19% and return on invested capital (ROIC) is -29.77%.
| Return on Equity (ROE) | -69.19% |
| Return on Assets (ROA) | -26.25% |
| Return on Invested Capital (ROIC) | -29.77% |
| Return on Capital Employed (ROCE) | -48.00% |
| Revenue Per Employee | 2.27M |
| Profits Per Employee | -2.56M |
| Employee Count | 12 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 22.98 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.77% in the last 52 weeks. The beta is 2.13, so DanCann Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.13 |
| 52-Week Price Change | -94.77% |
| 50-Day Moving Average | 1.72 |
| 200-Day Moving Average | 4.92 |
| Relative Strength Index (RSI) | 44.60 |
| Average Volume (20 Days) | 24,012 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DanCann Pharma had revenue of SEK 11.33 million and -12.82 million in losses. Loss per share was -3.21.
| Revenue | 11.33M |
| Gross Profit | -608,411 |
| Operating Income | -10.99M |
| Pretax Income | -12.82M |
| Net Income | -12.82M |
| EBITDA | -7.88M |
| EBIT | -10.99M |
| Loss Per Share | -3.21 |
Balance Sheet
The company has 5.34 million in cash and n/a in debt, giving a net cash position of 5.34 million or 1.34 per share.
| Cash & Cash Equivalents | 5.34M |
| Total Debt | n/a |
| Net Cash | 5.34M |
| Net Cash Per Share | 1.34 |
| Equity (Book Value) | 22.46M |
| Book Value Per Share | 5.63 |
| Working Capital | 4.19M |
Cash Flow
| Operating Cash Flow | -8.04M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -5.37%, with operating and profit margins of -97.03% and -113.21%.
| Gross Margin | -5.37% |
| Operating Margin | -97.03% |
| Pretax Margin | -113.21% |
| Profit Margin | -113.21% |
| EBITDA Margin | -69.55% |
| EBIT Margin | -97.03% |
| FCF Margin | n/a |
Dividends & Yields
DanCann Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,718.02% |
| Shareholder Yield | -2,718.02% |
| Earnings Yield | -154.33% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on February 24, 2025. It was a reverse split with a ratio of 0.001.
| Last Split Date | Feb 24, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.001 |
Scores
DanCann Pharma has an Altman Z-Score of 2.56. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.56 |
| Piotroski F-Score | n/a |